Haemolytic uraemic syndrome is a serious condition that requires quick recognition and proper medical support to protect the kidneys and other organs from lasting damage. Understanding what treatments are available—from hospital-based supportive care to newer targeted medicines—can help patients and families navigate this challenging illness.

Understanding Treatment Goals and Approaches

When someone develops haemolytic uraemic syndrome, often shortened to HUS, the main goal of treatment is to support the body while it recovers from the damage caused by this condition. HUS affects the small blood vessels, particularly in the kidneys, destroying red blood cells and reducing the number of platelets, which are tiny cells that help blood clot. This process can lead to acute kidney injury, meaning the kidneys suddenly lose their ability to filter waste from the blood properly.^[1]

Treatment decisions depend on several factors including what caused the HUS, how severe the symptoms are, the patient’s age, and which organs are affected. Young children, who are the most common patients with HUS, often respond well to supportive care when treatment begins quickly. Adults may experience more complex symptoms and complications, especially older individuals.^[2]

Medical professionals recognize that there are different types of HUS, each requiring slightly different approaches. The most common type, called typical HUS, is usually triggered by an infection with bacteria that produce Shiga toxin, most often a strain of Escherichia coli known as E. coli O157:H7. Another form, called atypical HUS or aHUS, is much rarer and is caused by problems with the body’s immune system, specifically the complement pathway, which is part of the body’s defense against infections.^[3]

Doctors and medical societies have developed standard approaches for treating HUS based on years of experience and research. At the same time, researchers continue to explore new therapies through clinical trials, seeking better ways to protect the kidneys and other organs from damage and to improve long-term outcomes for patients.

Standard Treatment for Haemolytic Uraemic Syndrome

The cornerstone of treating HUS, particularly the typical form caused by bacterial infection, is comprehensive supportive care in a hospital setting. This means helping the body maintain its functions while it heals naturally, rather than using specific drugs to target the underlying problem.^[9]

One of the most important aspects of supportive care is managing fluids and minerals in the body. Because the kidneys often cannot remove fluids and waste products properly during HUS, doctors carefully monitor how much fluid a patient receives. Some patients may need fluids given directly into their veins through an intravenous line, while others might need restrictions if their kidneys are severely affected and fluid is building up in the body.^[9]

Blood transfusions play a vital role in managing HUS. When red blood cells are destroyed faster than the body can replace them, a condition called anemia develops. This can cause extreme tiredness, pale skin, and shortness of breath. Doctors can give red blood cell transfusions through a vein to restore healthy blood levels and help the patient feel better. These transfusions are considered safe and effective for treating the anemia that accompanies HUS.^[9]

Platelet transfusions are handled differently. Platelets are blood cells that help stop bleeding, and HUS causes platelet levels to drop, a condition known as thrombocytopenia. However, doctors generally avoid giving platelet transfusions unless the patient is actively bleeding. This cautious approach exists because adding more platelets might potentially worsen the formation of small blood clots in the blood vessels, which is part of the disease process itself.^[10]

When kidney function becomes severely impaired and waste products build up dangerously in the blood, dialysis becomes necessary. Dialysis is a procedure that artificially filters the blood, doing the work that damaged kidneys cannot do. About half of children with typical HUS need dialysis during their illness. The good news is that this kidney damage is often temporary, and many patients eventually recover enough kidney function to stop dialysis. However, during the acute phase of illness, dialysis can be lifesaving.^[15]

Nutrition support is another critical component of treatment. Patients with HUS, especially children, may feel too sick to eat and may be vomiting. Doctors can provide nutrition through a vein, called parenteral nutrition, to ensure the body receives the calories and nutrients it needs to heal. This is particularly important during the acute phase when the patient cannot eat normally.^[9]

Managing blood pressure is essential because HUS often causes high blood pressure, which can further damage the kidneys and other organs. Doctors may prescribe blood pressure medications to keep readings in a safe range. These medications, which might continue long after the acute illness resolves, help protect the kidneys from additional harm and reduce the risk of long-term complications.^[9]

For atypical HUS, which has a different underlying cause related to the immune system’s complement pathway, the treatment approach includes additional therapies beyond supportive care. Historically, doctors used a treatment called plasma exchange or plasmapheresis, where the patient’s blood is filtered to remove harmful substances and then mixed with healthy plasma from donors before being returned to the body. Plasma exchange helps because it removes the dysfunctional proteins causing the complement system to malfunction and replaces them with normal proteins from donor plasma.^[11]

Plasma exchange treatments typically need to be performed daily or every other day during the acute illness, and some patients require ongoing treatments for weeks or even months. The procedure is similar to dialysis in that blood is removed from the body, processed, and returned. While plasma exchange has improved outcomes for many patients with atypical HUS, it requires specialized equipment and trained staff, and it carries some risks including allergic reactions and infections from the intravenous lines needed to access the bloodstream.^[11]

It is important to note that plasma therapy is specifically contraindicated, meaning it should not be used, in cases of HUS caused by Streptococcus pneumoniae infection. This is a specific bacterial cause of HUS that is different from E. coli. In these cases, plasma from donors may actually contain antibodies that can make the disease worse rather than better.^[11]

The duration of hospitalization varies widely depending on how sick the patient is and how quickly they respond to treatment. Some patients may need only a week or two in the hospital, while others, particularly those requiring dialysis or those with severe complications affecting multiple organs, may need several weeks or even months of hospital care. Most children with typical HUS recover within a few weeks, though complete recovery can take months.^[6]

Advanced Treatments Available Through Clinical Approval

A major breakthrough in treating atypical HUS came with the development of medications called complement inhibitors. These drugs specifically target the faulty immune response that causes atypical HUS by blocking part of the complement pathway. Two such medications have received approval from the United States Food and Drug Administration (FDA) for treating atypical HUS in both children and adults.^[9]

The first of these medicines is eculizumab, marketed under the brand name Soliris. Eculizumab is a monoclonal antibody, which is a laboratory-made protein that mimics the immune system’s ability to fight harmful substances. Eculizumab works by blocking a specific protein in the complement cascade called C5. When C5 is blocked, it cannot trigger the formation of the membrane attack complex, which is the end product of the complement system that damages cells. By preventing this final step, eculizumab protects the lining of blood vessels and blood cells from destruction.^[7]

Eculizumab is given as an intravenous infusion, meaning it is delivered slowly into a vein over a period of time. The treatment schedule typically begins with weekly infusions for the first few weeks, followed by infusions every two weeks for maintenance therapy. Because atypical HUS is usually a chronic condition related to genetic abnormalities, patients often need to continue receiving eculizumab indefinitely to prevent the disease from coming back.^[7]

The second approved complement inhibitor is ravulizumab, sold under the brand name Ultomiris. Ravulizumab works in a very similar way to eculizumab—it also blocks the C5 protein in the complement pathway. However, ravulizumab was designed to last longer in the body, which means patients can receive infusions less frequently. Instead of every two weeks, ravulizumab can be given every eight weeks for maintenance therapy, which can significantly improve quality of life and reduce the burden of frequent hospital or clinic visits.^[9]

Both eculizumab and ravulizumab have demonstrated effectiveness in clinical studies. Patients treated with these medications have shown improvement in blood cell counts, kidney function, and the need for dialysis or plasma exchange. Many patients who were dependent on dialysis have been able to stop dialysis treatment after beginning complement inhibitor therapy. The medications have also reduced the risk of serious complications affecting the brain, heart, and other organs.^[7]

Side effects of complement inhibitor therapy can vary from person to person. Common side effects include headache, upper respiratory infections such as colds or sinus infections, nausea, diarrhea, and back pain. These side effects are generally manageable and often improve over time. The most serious risk remains meningococcal infection, which is why vaccination and awareness of warning signs are so critical. Some patients may also experience allergic reactions to the infusion itself, though this is relatively uncommon.^[7]

The decision to use complement inhibitors is typically made when a patient is diagnosed with atypical HUS. Doctors may perform genetic testing to confirm that the patient has mutations or abnormalities in genes related to the complement pathway. However, treatment should not be delayed while waiting for genetic test results if a patient has clinical signs of atypical HUS, because early treatment can prevent permanent organ damage.^[10]

Questions remain about how long patients should continue taking complement inhibitors. Some doctors and patients have attempted to stop the medication after a period of stability, but there is a risk that the disease will return when treatment stops. Studies are ongoing to better understand which patients might be able to safely discontinue treatment and which need lifelong therapy. For now, many specialists recommend continuing treatment indefinitely for most patients with atypical HUS.^[7]

Access to these complement inhibitor medications varies by country and healthcare system. In the United States and many European countries, eculizumab and ravulizumab are approved for atypical HUS. However, these medications are very expensive, which can create barriers to access even in wealthy countries. Patient assistance programs and health insurance coverage vary, and navigating the financial aspects of treatment can be challenging for families and patients.^[17]

Emerging Treatments and Ongoing Clinical Research

While the approved complement inhibitors represent a major advance, researchers continue to explore new treatments for HUS through clinical trials. These studies are essential for developing better therapies, reducing side effects, and potentially finding cures for different forms of HUS.

Clinical trials for HUS typically progress through several phases. Phase I trials focus primarily on safety, testing a new drug or treatment approach in a small number of people to evaluate whether it is safe and to determine appropriate dosing. These trials help researchers understand how the body processes the medication and what side effects might occur.^[3]

Once a treatment appears safe, it moves to Phase II trials, which evaluate how well the treatment works. These studies include more participants and look at specific measures of effectiveness, such as improvement in kidney function, reduction in the need for dialysis, or improvement in blood cell counts. Phase II trials also continue to monitor safety and side effects in a larger group of patients.^[3]

Phase III trials are large studies that compare the new treatment to current standard treatments or to placebo (an inactive substance). These trials involve many patients across multiple medical centers and sometimes span several countries. The goal is to definitively prove whether the new treatment is better than, as good as, or inferior to existing options. Regulatory agencies like the FDA use Phase III trial results to decide whether to approve a new treatment for general use.^[3]

After a treatment is approved and in general use, Phase IV trials or post-marketing studies continue to collect information about long-term effects, rare side effects that might not have been apparent in earlier trials, and how the treatment performs in real-world settings across diverse patient populations.

Currently, researchers are investigating several promising approaches for HUS. Some studies are looking at alternative ways to block the complement system, either by targeting different proteins in the cascade or by using different types of molecules. Other research focuses on understanding the genetic causes of atypical HUS better, which could lead to more personalized treatment approaches tailored to a patient’s specific genetic profile.^[10]

Scientists are also exploring whether medications that protect the lining of blood vessels, called endothelial protective agents, might help prevent or reduce the damage caused by HUS. The blood vessel lining, or endothelium, is where much of the damage from HUS occurs, and protecting these cells could potentially prevent the cascade of problems that leads to kidney failure and other complications.

Eligibility for clinical trials varies depending on the specific study. Generally, patients must meet certain criteria such as having a confirmed diagnosis of HUS (either typical or atypical depending on the study), being within a certain age range, and not having certain other medical conditions that might interfere with the study results. Some trials are looking specifically at children, while others enroll only adults or include both age groups.^[3]

Patients interested in participating in clinical trials can ask their doctors about available studies or search clinical trial registries. In the United States, the website ClinicalTrials.gov maintains a database of ongoing studies. Similar registries exist in Europe and other regions. Participating in a clinical trial can provide access to new treatments before they are widely available, though participants should understand that experimental treatments may not work and could have unknown side effects.

Most common treatment methods

• Supportive hospital care
  • Careful monitoring of fluid balance with intravenous fluids when needed and fluid restriction when kidneys cannot eliminate excess fluid properly
  • Nutrition provided through a vein when patients cannot eat normally
  • Close monitoring of kidney function, blood counts, and other organ systems
  • Management of complications such as high blood pressure, seizures, or heart problems
• Blood product transfusions
  • Red blood cell transfusions to treat anemia caused by destruction of red blood cells
  • Cautious approach to platelet transfusions, generally used only when active bleeding occurs
• Dialysis therapy
  • Hemodialysis to filter waste products and excess fluid from blood when kidneys cannot function adequately
  • Temporary measure in most cases of typical HUS, with many patients recovering kidney function
  • May be needed long-term in severe cases or when permanent kidney damage occurs
• Plasma exchange (for atypical HUS)
  • Removal of patient’s plasma and replacement with healthy donor plasma
  • Removes dysfunctional complement proteins and provides normal proteins
  • Requires specialized equipment and trained personnel
  • Typically performed daily or every other day during acute illness
• Complement inhibitor therapy
  • Eculizumab (Soliris) blocks C5 protein in complement pathway, given by intravenous infusion initially weekly then every two weeks
  • Ravulizumab (Ultomiris) works similarly to eculizumab but lasts longer in body, allowing for less frequent dosing every eight weeks
  • Approved specifically for atypical HUS in children and adults
  • Requires meningococcal vaccination before starting treatment
  • Often continued indefinitely to prevent disease recurrence
• Blood pressure management
  • Medications to control high blood pressure that commonly develops with HUS
  • Important for protecting kidneys from further damage
  • May be needed for months or years after acute illness resolves
• Kidney transplantation
  • Option for patients who progress to end-stage kidney disease
  • Generally safe and effective with low recurrence rates for typical HUS
  • Atypical HUS patients may need continued complement inhibitor therapy to prevent disease recurrence in transplanted kidney

Long-Term Outlook and Follow-Up Care

The prognosis for patients with HUS depends largely on the type of HUS, how quickly treatment begins, and how severely the kidneys and other organs are affected during the acute illness. Most children with typical HUS caused by E. coli infection recover completely with proper supportive care. Studies show that less than five percent of patients with typical HUS die during the acute illness in developed countries with access to modern medical care.^[5]

However, even children who appear to recover fully need long-term monitoring. About 25 percent of patients who survive typical HUS may develop some degree of long-term kidney problems. These can range from mild abnormalities detectable only through laboratory tests to chronic kidney disease that eventually requires dialysis or transplantation. Blood pressure problems, protein in the urine, and reduced kidney function may not become apparent until months or years after the initial illness.^[6]

For this reason, doctors recommend that all patients who have had HUS undergo regular follow-up appointments that include blood pressure checks, urine tests to look for protein or blood, and blood tests to measure kidney function. These follow-up visits typically occur frequently at first, then less often as time passes if the patient remains stable. However, some degree of monitoring usually continues for many years or even lifelong.

Atypical HUS generally has a more serious prognosis than typical HUS. Before the availability of complement inhibitor therapy, many patients with atypical HUS progressed to kidney failure requiring dialysis or transplantation. Some patients experienced complications affecting the brain, heart, and other organs. With the introduction of eculizumab and ravulizumab, outcomes have improved dramatically, though these medications must often be continued indefinitely.^[7]

Adults with HUS, whether typical or atypical, tend to have more complicated courses than children. They are more likely to develop severe complications, to require dialysis, and to have lasting kidney damage. Older adults in particular face higher risks of serious outcomes. The reasons for these differences are not completely understood but may relate to other health conditions that are more common in adults and to how the aging body responds to serious illness.^[5]

Patients who have had HUS should be aware of situations that might trigger a recurrence or worsen kidney function. These include severe dehydration, certain medications that can harm the kidneys, and new infections. Women who have had atypical HUS face special considerations if they become pregnant, as pregnancy can trigger recurrence of the disease. Close monitoring throughout pregnancy and the postpartum period is essential, and some women may need to continue or restart complement inhibitor therapy during and after pregnancy.^[17]

For patients who develop end-stage kidney disease and require kidney transplantation, outcomes are generally good for typical HUS, with low rates of disease recurrence in the transplanted kidney. Atypical HUS patients face a higher risk of the disease recurring in the transplanted kidney, but this risk can be substantially reduced with complement inhibitor therapy started before or at the time of transplantation and continued afterward.^[11]

Living with a history of HUS or with ongoing atypical HUS requiring regular treatment can affect quality of life. Some patients experience fatigue, difficulty concentrating, and emotional challenges. Children may miss significant amounts of school during and after the acute illness. Support from family, friends, healthcare providers, and patient support organizations can make a meaningful difference. Connecting with other patients who have gone through similar experiences, whether through online communities or in-person support groups, can provide valuable emotional support and practical advice.^[17]